1. Home
  2. KPTI vs TMQ Comparison

KPTI vs TMQ Comparison

Compare KPTI & TMQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • TMQ
  • Stock Information
  • Founded
  • KPTI 2008
  • TMQ 2004
  • Country
  • KPTI United States
  • TMQ Canada
  • Employees
  • KPTI N/A
  • TMQ N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • TMQ Precious Metals
  • Sector
  • KPTI Health Care
  • TMQ Basic Materials
  • Exchange
  • KPTI Nasdaq
  • TMQ Nasdaq
  • Market Cap
  • KPTI 81.1M
  • TMQ 83.6M
  • IPO Year
  • KPTI 2013
  • TMQ N/A
  • Fundamental
  • Price
  • KPTI $0.59
  • TMQ $1.32
  • Analyst Decision
  • KPTI Strong Buy
  • TMQ
  • Analyst Count
  • KPTI 4
  • TMQ 0
  • Target Price
  • KPTI $5.00
  • TMQ N/A
  • AVG Volume (30 Days)
  • KPTI 760.2K
  • TMQ 365.0K
  • Earning Date
  • KPTI 02-19-2025
  • TMQ 02-14-2025
  • Dividend Yield
  • KPTI N/A
  • TMQ N/A
  • EPS Growth
  • KPTI N/A
  • TMQ N/A
  • EPS
  • KPTI N/A
  • TMQ N/A
  • Revenue
  • KPTI $148,442,000.00
  • TMQ N/A
  • Revenue This Year
  • KPTI $4.47
  • TMQ N/A
  • Revenue Next Year
  • KPTI $7.35
  • TMQ N/A
  • P/E Ratio
  • KPTI N/A
  • TMQ N/A
  • Revenue Growth
  • KPTI 1.77
  • TMQ N/A
  • 52 Week Low
  • KPTI $0.58
  • TMQ $0.25
  • 52 Week High
  • KPTI $1.70
  • TMQ $1.48
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 39.75
  • TMQ 56.25
  • Support Level
  • KPTI $0.58
  • TMQ $1.26
  • Resistance Level
  • KPTI $0.65
  • TMQ $1.38
  • Average True Range (ATR)
  • KPTI 0.05
  • TMQ 0.07
  • MACD
  • KPTI -0.00
  • TMQ -0.00
  • Stochastic Oscillator
  • KPTI 34.46
  • TMQ 41.84

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-lead-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

Share on Social Networks: